In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...
Jim Cramer labels Vertex Pharmaceuticals a buy, citing its impactful mission. Analysts project a 22.33% upside for Vertex stock, despite current bearish momentum. Memorial Day Special: Access your ...
Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has ...
Want an edge in trading? Follow the Big Money. What’s Big Money? Said simply, it’s when a stock rises due to institutional demand. Top stocks tend to attract savvy investors. You see, fund managers ...
Despite commanding over 90% of its revenue from its cystic fibrosis drug franchise, Vertex has been unable to fend off investor skepticism. In 2024, the company made waves with CASGEVY, the first gene ...
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results